Cell Lysis and Fractionation Market Report 2026

The cell lysis and fractionation market size has grown strongly in recent years. It will grow from $3.69 billion in 2025 to $3.95 billion in 2026 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to increasing molecular biology research activity, growth in proteomics studies, rising use of nucleic acid purification techniques, expansion of life science laboratories, increased demand for standardized sample preparation.

The cell lysis and fractionation market size is expected to see strong growth in the next few years. It will grow to $5.16 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing investments in proteomics and genomics research, growing adoption of automated sample preparation, rising focus on high-throughput analysis, expansion of biopharmaceutical research pipelines, increasing use of integrated laboratory systems. Major trends in the forecast period include increasing adoption of automated cell lysis systems, rising demand for high-efficiency protein extraction, growing use of chemical and mechanical lysis methods, expansion of fractionation-based sample preparation, enhanced focus on sample integrity.

The increasing emphasis on personalized medicine is anticipated to drive the growth of the cell lysis and fractionation markets in the coming years. Personalized medicine is an evolving medical approach that leverages an individual’s genetic profile to guide disease diagnosis and treatment. It focuses on customizing medical decisions and therapies based on the unique characteristics of each patient, particularly their genetic composition. Cell lysis and fractionation play a vital role in precision medicine by enabling the separation and analysis of specific subcellular components from patient samples, such as proteins, organelles, and nucleic acids. This capability allows researchers and healthcare professionals to study the molecular mechanisms underlying diseases and develop tailored therapies based on the distinct molecular features of individual patients. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, in 2023, the Food and Drug Administration (FDA) approved seven new personalized cancer treatments out of a total of 26 personalized therapies, representing a notable increase compared to the 12 approvals in 2022. Therefore, the growing focus on personalized medicine is fueling the expansion of the cell lysis and fractionation markets.

The increasing demand from the biopharmaceutical industry is expected to further support the growth of the cell lysis and fractionation market. The biopharmaceutical industry comprises organizations that develop, manufacture, and commercialize biologically derived drugs and therapies using biotechnology. Growth in this industry is being driven by the rising incidence of chronic and complex diseases, which is increasing demand for advanced and targeted treatment options. Cell lysis and fractionation support biopharmaceutical activities by disrupting cells to release and separate intracellular biomolecules, including proteins, enzymes, and nucleic acids, which are critical for drug discovery, biologics manufacturing, and research processes. For instance, in January 2024, according to IQVIA, a US-based biopharmaceutical development services provider, global spending on biotechnology is projected to surpass $892 billion by 2028. Therefore, the growing demand from the biopharmaceutical sector is contributing to the expansion of the cell lysis and fractionation market.

Major companies operating in the cell lysis and fractionation market are concentrating on the introduction of advanced solutions, such as cell and gene therapy (CGT) viral vector lysis kits, to strengthen their competitive position. These lysis kits provide a streamlined adeno-associated virus (AAV) lysis approach that enhances standard operating procedures (SOPs), quality control, and safety while standardizing bioprocessing workflows. For instance, in July 2023, QIAGEN, a Germany-based provider of sample and assay technologies, launched a new CGT Viral Vector Lysis Kit that enables accurate and consistent quantification of virus titers across multiple serotypes starting from cell lysates. This CGT viral vector lysis kit complements QIAGEN’s expanding digital PCR portfolio for the biopharmaceutical industry, which includes QIAcuity Residual DNA Quantification Kits for detecting host cell DNA carryover and multiple QIAcuity Cell and Gene Therapy (CGT) digital PCR assays for adeno-associated virus (AAV) titer quantification.

Major companies operating in the cell lysis and fractionation market are Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Lonza Group AG, Illumina Inc., Beckman Coulter Inc., PerkinElmer Inc., IDEX Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Takara Bio Inc., Abcam plc, Cell Signaling Technology Inc., BioVision Inc., Diagenode LLC, Claremont BioSolutions LLC, Norgen Biotek Corp., Qsonica LLC, Labfreez Instruments Group Co. Ltd.

North America was the largest region in the cell lysis and fractionation market in 2025. The regions covered in the cell lysis and fractionation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell lysis and fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell lysis and fractionation market by increasing costs of imported homogenizers, sonicators, centrifuges, reagents, and precision laboratory instruments. Research laboratories and biopharmaceutical companies in North America and Europe are most affected due to reliance on imported equipment, while Asia-Pacific faces higher setup costs for advanced research facilities. These tariffs are raising laboratory operational expenses and delaying equipment upgrades. However, they are also driving local manufacturing of laboratory tools, regional reagent production, and innovation in cost-effective lysis and fractionation solutions.

The cell lysis and fractionation market research report is one of a series of new reports that provides cell lysis and fractionation market statistics, including cell lysis and fractionation industry global market size, regional shares, competitors with a cell lysis and fractionation market share, detailed cell lysis and fractionation market segments, market trends and opportunities, and any further data you may need to thrive in the cell lysis and fractionation industry. This cell lysis and fractionation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell lysis and fractionation refer to tools and techniques used to disrupt cell membranes and separate cellular components for a wide range of research applications. These processes involve breaking open cells and isolating their internal components, enabling researchers to analyze specific proteins, organelles, or nucleic acids.

The main types of cell lysis and fractionation include mammalian cells and microbial cells. Mammalian cells are eukaryotic cells derived from mammals and are widely used in cell culture and the biomanufacturing of therapeutic proteins and viral vaccines. These processes support applications such as nucleic acid purification and isolation and protein purification and isolation, and are utilized by end users including research laboratories and institutes, biopharmaceutical companies, and biotechnology companies.

The cell lysis and fractionation market consists of revenues earned by entities by providing cellular contents extraction, cytoplasmic separation, and cell disruption. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and fractionation market also includes sales of cell lysis instruments, cell lysis reagents, and consumables. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.